Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | MAOB | P27338 | 7/20 | 0.86 |
| ▸ | MAOA | P21397 | 4/20 | 0.86 |
| ▸ | POLB | P06746 | 1/20 | 0.86 |
| ▸ | RAB9A | P51151 | 1/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.82 |
| ▸ | HPGD | P15428 | 3/20 | 0.82 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.75 |
| ▸ | HTT | P42858 | 3/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.72 |
| ▸ | PKM | P14618 | 2/20 | 0.72 |
| ▸ | ATM | Q13315 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4,4'-Dimethylchalcone SCHEMBL979560 | 1.00 | MAPT (1.00) | MAPTMAOBMAOAPOLBRAB9A | |
| SCHEMBL22098902 | 0.94 | MAPT (0.89) | MAPTMAOBMAOAPOLBRAB9A | |
| SCHEMBL22099225 | 0.94 | MAPT (0.89) | MAPTMAOBMAOAPOLBRAB9A | |
| SCHEMBL548040 | 0.93 | MAPT (1.00) | MAPTMAOBMAOAPOLBRAB9A | |
| SCHEMBL8965069 | 0.93 | MAPT (1.00) | MAPTMAOBMAOAPOLBRAB9A | |
| SCHEMBL25194931 | 0.93 | MAPT (0.86) | MAPTMAOBMAOAPOLBRAB9A | |
| SCHEMBL10497491 | 0.93 | MAPT (0.86) | MAPTMAOBMAOAPOLBRAB9A | |
| SCHEMBL548041 | 0.93 | MAPT (1.00) | MAPTMAOBMAOAPOLBRAB9A | |
| SCHEMBL10299698 | 0.93 | MAPT (0.86) | MAPTMAOBMAOAPOLBRAB9A | |
| SCHEMBL8480925 | 0.93 | MAPT (0.86) | MAPTMAOBMAOAPOLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115400106-B | Application of natural compound and composition thereof in removing aging cells | 清华大学 | 2024-01-19 | — | — | CN | disclosed |
| US-11661407-B2 | Process for the preparation of pyrylium salts | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2023-05-30 | — | — | US | disclosed |
| CN-115400106-A | Application of natural compound and composition thereof in removing senescent cells | 清华大学 | 2022-11-29 | — | — | CN | disclosed |
| CN-115141621-A | Oil-based fracturing fluid, multi-stage fracturing method and method for online monitoring productivity of reservoir intervals | 中国石油化工股份有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-114524829-A | Preparation method of imidazo [2,1-b ] thiazole derivative | 新疆大学 | 2022-05-24 | — | — | CN | disclosed |
| US-11299675-B2 | Polymerizable polar compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2022-04-12 | — | — | US | disclosed |
| CN-107922830-B | Electrochromic compounds and optical articles containing them | 依视路国际公司 | 2021-08-20 | — | — | CN | disclosed |
| US-11028323-B2 | Liquid crystal aligning agent containing crosslinking agent and polymer that has site having isocyanate group and/or blocked isocyanate group and site having photoreactivity, liquid crystal alignment film, and liquid crystal display element | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2021-06-08 | — | — | US | disclosed |
| US-20210132421-A1 | LIQUID CRYSTAL DISPLAY DEVICE | SHARP KABUSHIKI KAISHA (JP) | 2021-05-06 | — | — | US | disclosed |
| US-20210087158-A1 | A PROCESS FOR THE PREPARATION OF PYRYLIUM SALTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2021-03-25 | — | — | US | disclosed |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Robinson, Thomas Philip (US) | 2009-01-15 | — | — | US | disclosed |
| US-7432303-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Bowen, J. Phillip (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432303-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Bowen, J. Phillip (US) | 2008-10-07 | — | — | US | disclosed |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2005-07-07 | — | — | US | disclosed |
| US-6906105-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP (US) | 2005-06-14 | — | — | US | disclosed |
| US-6462075-B1 | USE OF CHALCONE AND ITS DERIVATIVES AS ANTITUMOR/ANTICANCER AGENTS AND TO TREAT A NUMBER OF CONDITIONS OR DISEASE STATES IN WHICH ANGIOGENESIS IS A FACTOR INCLUDING PSORIASIS, ACNE, ROSACEA, WARTS, ECZEMA, HEMANGIOMAS AND LYMPHANGIOGENESIS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2002-10-08 | — | — | US | disclosed |
| EP-0693502-B1 | Catalyst component for the polymerization of alpha-olefins and a process for preparing alpha-olefin polymers with use of same | MITSUBISHI CHEM CORP (JP) | 1997-11-05 | — | — | EP | disclosed |
| US-5594081-A | METALLOCENES | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-01-14 | — | — | US | disclosed |
| EP-0693502-A1 | Catalyst component for the polymerization of alpha-olefins and a process for preparing alpha-olefin polymers with use of same | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-01-24 | — | — | EP | disclosed |
| US-5045239-A | Chalcone derivative | NIPPON OIL AND FATS CO., LTD. (JP) | 1991-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | MAPT 1274/4885MAOB 2526/4885MAOA 1978/4885 |
| US-20210087158-A1 | A PROCESS FOR THE PREPARATION OF PYRYLIUM SALTS | IPO5, SF3B5, CYP4F11 | MAPT 2365/4885MAOB 2307/4885MAOA 3394/4885 |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | MAPT 341/4885MAOB 1509/4885MAOA 1059/4885 |
| US-11661407-B2 | Process for the preparation of pyrylium salts | SF3B5, IPO5, CYP4F11 | MAPT 2455/4885MAOB 2613/4885MAOA 3764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.